Sermorelin vs MK-677 (Ibutamoren): What to Do When One Fails

How Each Drug Actually Stimulates Growth Hormone

Sermorelin and MK-677 both raise growth hormone output, but they do so through entirely different receptor systems. That difference explains why one can fail while the other still works, and why combining them produces additive rather than redundant effects.

Sermorelin: GHRH Receptor Agonism

Sermorelin acetate is a 29-amino-acid synthetic analogue of endogenous growth hormone-releasing hormone (GHRH 1-29). It binds the GHRH receptor on pituitary somatotrophs and triggers a pulse of GH secretion that mirrors the body's overnight rhythm [1]. Because the pituitary's own somatostatin feedback loop remains intact, sermorelin carries a low risk of GH excess.

Walker et al. (Pediatrics 1990, N=121) showed that nightly subcutaneous sermorelin at 30 mcg/kg produced significant height velocity increases in GH-deficient children, establishing pituitary responsiveness as the key predictor of efficacy [1]. The same pituitary dependence that makes sermorelin physiologically elegant is also its main liability: a somatotroph-depleted or aged pituitary may simply not respond.

MK-677: Ghrelin Receptor Agonism

MK-677 (ibutamoren) is a non-peptide, orally active agonist at the ghrelin receptor (GHS-R1a) [2]. It drives GH release through a mechanism entirely separate from GHRH-R, which means it can stimulate GH secretion even when the GHRH pathway is blunted [3]. Murphy et al. (J Clin Endocrinol Metab 1998, N=32) demonstrated that MK-677 25 mg/day for 2 years raised serum IGF-1 by approximately 60% and increased GH pulse amplitude without altering pulse frequency, confirming a sustained secretagogue effect via the ghrelin axis [4].

Because GHS-R1a is expressed throughout the body, including in the hypothalamus, hippocampus, and gut, MK-677 produces off-target effects that sermorelin does not: increased appetite, elevated fasting glucose, and water retention are the most clinically significant [5].

Why the Mechanisms Matter Clinically

A patient who responds poorly to sermorelin is most likely failing at the pituitary level. A patient who responds poorly to MK-677 is more often failing at the receptor level due to desensitization, or at the metabolic level due to insulin resistance blunting IGF-1 bioavailability [6]. These are different problems that require different solutions.

Comparing Efficacy Data Head to Head

No published randomized controlled trial has directly compared sermorelin to MK-677 in the same population. The best available evidence comes from parallel cohort data and the two key trials cited above.

IGF-1 Outcomes

Murphy et al. 1998 (N=32, healthy elderly men) showed MK-677 25 mg orally raised mean IGF-1 from approximately 116 ng/mL to approximately 186 ng/mL at 12 months, a 60.3% increase [4]. Sermorelin trials in GH-deficient adults typically report IGF-1 increases of 30 to 50% from baseline when dosed at 0.2 to 0.3 mg/night subcutaneously [7].

On raw IGF-1 elevation, MK-677 appears more potent. The clinical significance of that difference depends on baseline pituitary reserve, age, body composition, and whether the target is GH deficiency correction or performance optimization.

Body Composition

In Murphy et al., MK-677 produced a statistically significant increase in lean body mass (mean 1.6 kg at 12 months, P<0.05) and a reduction in fat mass, with the lean mass gain persisting at 24 months [4]. Sermorelin's body composition data, reported in Walker et al. And subsequent adult studies, shows similar lean mass accretion when IGF-1 is normalized, but the effect size is generally smaller at standard doses [1].

Sleep Architecture

Both agents improve slow-wave sleep, which is when most endogenous GH secretion occurs. MK-677's effect on sleep was documented in a crossover study by Copinschi et al. (Sleep 1997), where a single dose increased REM sleep and stage IV sleep measurably in healthy young men [8]. Sermorelin's sleep benefit is indirect, mediated by the GH pulse it triggers around sleep onset rather than a direct CNS effect.

Glucose Metabolism

This is the clearest difference between the two drugs. Sermorelin does not meaningfully alter fasting glucose or insulin sensitivity in non-diabetic adults at therapeutic doses [9]. MK-677 raises fasting glucose by approximately 0.3 mmol/L and increases fasting insulin, consistent with mild insulin resistance, an effect that was sustained across 24 months in Murphy et al. [4]. In patients with pre-diabetes or metabolic syndrome, this is a clinically important distinction [10].

What "Failure" Looks Like for Each Agent

Defining failure precisely prevents premature switching and also prevents patients from staying on an ineffective protocol too long.

Defining Sermorelin Failure

Sermorelin failure is defined as less than 20% increase in serum IGF-1 from baseline after 12 weeks of correctly dosed, correctly administered nightly injections. Common causes include:

• Pituitary somatotroph depletion (age-related or iatrogenic)
• Injection technique errors (room-temperature storage, incorrect reconstitution)
• Simultaneous high-dose glucocorticoid use, which suppresses GHRH signaling [11]
• Obesity with BMI above 35, where somatostatin tone is chronically elevated and blunts GHRH-R responses [12]

Before declaring sermorelin a failure, confirm IGF-1 was drawn fasting in the morning, at least 8 hours after the last injection, and that the vial was stored refrigerated and used within 30 days of reconstitution.

Defining MK-677 Failure

MK-677 failure presents in two distinct patterns. The first is primary non-response: IGF-1 does not rise meaningfully despite 8 to 12 weeks of 12.5 to 25 mg/day dosing. This is uncommon and may reflect GHS-R1a polymorphisms [13]. The second pattern is secondary failure after initial response: IGF-1 rises for the first 3 to 6 months, then plateaus or declines toward baseline. This is more common and reflects receptor downregulation [14].

MK-677 is also considered a "failure" for practical purposes when metabolic side effects become intolerable: persistent edema, fasting glucose above 100 mg/dL in a previously normoglycemic patient, or sustained increases in appetite that cause unintended weight gain [10].

The Decision Framework: Stay, Switch, or Combine

When a patient reports that one agent is no longer working, the clinical decision follows a four-step process.

Step 1: Confirm the Failure Is Real

Pull a fasting morning IGF-1 and compare it to the documented baseline. If IGF-1 is at least 20% above baseline and within age-adjusted reference range, the protocol is working even if the patient does not feel subjective benefit. Subjective plateau without biochemical plateau is a different problem, often related to sleep quality, caloric intake, or training stimulus, not the peptide.

Step 2: Identify the Failure Mode

For sermorelin non-responders: check IGF-1 binding proteins (especially IGFBP-3), free IGF-1, and morning cortisol. High cortisol or high IGFBP-3 suppresses bioavailable IGF-1 even when total IGF-1 rises [15]. For MK-677 non-responders: check fasting glucose, HbA1c, and insulin. Insulin resistance reduces IGF-1 bioavailability by altering hepatic IGF-1 synthesis [16].

Step 3: Choose the Correct Intervention

If sermorelin is failing due to pituitary depletion: Switch to MK-677, which bypasses GHRH-R entirely. Start at 12.5 mg nightly for 4 weeks, then titrate to 25 mg if tolerated and IGF-1 response is insufficient.

If sermorelin is failing due to technique or storage errors: Correct the error and extend the trial by 8 more weeks before switching.

If MK-677 is failing due to receptor desensitization: Consider a 4-week drug holiday, then re-challenge. Alternatively, add sermorelin to the regimen at 0.2 mg nightly, which stimulates GH via a completely different receptor and may restore responsiveness to the overall GH axis [17].

If MK-677 is failing due to metabolic side effects: Switch to sermorelin. Sermorelin does not impair glucose metabolism and is the preferred agent in patients with pre-diabetes, metabolic syndrome, or who are taking metformin [9].

Step 4: Monitor the New Protocol Rigorously

After switching or adding an agent, draw a repeat IGF-1 at 8 weeks. If IGF-1 remains below the age-adjusted reference range midpoint after 12 weeks on the new protocol, consider referral to an endocrinologist to evaluate for true adult GH deficiency (AGHD) per the Endocrine Society's 2011 Clinical Practice Guideline, which specifies that AGHD diagnosis requires a stimulation test (insulin tolerance test or glucagon stimulation test) and that GH replacement with recombinant human GH may be indicated when secretagogues fail [18].

Safety Profiles Compared

Sermorelin Safety

Sermorelin's adverse effect profile is limited primarily to injection-site reactions (mild erythema in approximately 17% of users), transient facial flushing, and headache [19]. Because the hypothalamic-pituitary somatostatin feedback loop remains intact, sermorelin cannot produce the GH excess seen with exogenous GH administration. The FDA approved sermorelin (Geref) for GH deficiency in children, and adult off-label use has a well-characterized tolerability record [20].

IGF-1 above the age-adjusted upper limit of normal should prompt dose reduction. Sermorelin is contraindicated in patients with active malignancy, as with all GH secretagogues [21].

MK-677 Safety

MK-677's safety profile includes the glucose effects noted above, plus edema (reported in approximately 25% of users in Murphy et al.), increased appetite, and transient elevations in cortisol and prolactin [4]. The cortisol elevation is small (mean 17% above baseline in short-term studies) but relevant in patients being monitored for adrenal function [22].

MK-677 is not FDA-approved for any indication. It is currently classified as a research compound. The FDA issued a warning in 2023 regarding the sale of ibutamoren as a dietary supplement, citing lack of safety data for long-term use [23]. Prescribers operating within telehealth settings should document informed consent explicitly, including the investigational status of the compound [24].

Practical Dosing and Administration

Sermorelin Protocol

Standard adult dosing for off-label GH optimization is 0.2 to 0.3 mg (200 to 300 mcg) subcutaneously at bedtime, 5 nights per week [7]. Some protocols use 5 days on, 2 days off to preserve pituitary sensitivity. Sermorelin must be reconstituted with bacteriostatic water and refrigerated. Stability after reconstitution is approximately 30 days at 2 to 8°C [19].

MK-677 Protocol

MK-677 is taken orally, typically at 12.5 to 25 mg at bedtime to align the GH pulse with the natural nocturnal peak. Starting at 12.5 mg and titrating up after 4 weeks limits appetite and edema side effects [4]. Unlike sermorelin, MK-677 is stable at room temperature and requires no reconstitution, which improves adherence in patients who are needle-averse.

Combination Use

When used together, sermorelin and MK-677 produce additive GH stimulation because they act on distinct receptors. A combination protocol typically uses sermorelin 0.2 mg nightly plus MK-677 12.5 mg nightly, with IGF-1 monitoring at 6 and 12 weeks to ensure levels remain within the age-adjusted reference range [17]. Combination use is reserved for patients with documented low IGF-1 on monotherapy.

Monitoring Parameters and Lab Targets

Baseline labs before starting either agent should include: fasting IGF-1, fasting glucose, HbA1c, and a comprehensive metabolic panel. In patients over 50, add a PSA if male and a DEXA scan if body composition change is a primary goal [18].

On-treatment monitoring:

• IGF-1 at 8 weeks, then every 3 to 6 months
• Fasting glucose at 8 weeks on MK-677 (and at baseline)
• Blood pressure at each clinical contact (MK-677 can cause fluid retention and modest blood pressure increase) [5]
• Target IGF-1: age-adjusted mid-range per local laboratory reference intervals, typically 100 to 250 ng/mL for adults aged 30 to 60 [18]

The Endocrine Society's 2011 guideline states: "The goal of GH replacement is to normalize serum IGF-1 concentrations while avoiding symptoms and signs of GH excess" [18]. That benchmark applies whether the secretagogue is sermorelin, MK-677, or a combination.

Who Should Use Which Agent

Sermorelin is the first-line option when: the patient has intact pituitary reserve confirmed by IGF-1 response to a test dose, when glucose metabolism is already impaired, when the patient is on concurrent testosterone replacement therapy (TRT) and wants a physiologic GH stimulus to complement it, or when regulatory clarity matters because sermorelin is an FDA-approved molecule.

MK-677 is the better option when: the patient has documented GHRH-R pathway blunting (age-related or obesity-related), when needle aversion makes nightly injections impractical, when sleep quality is a primary complaint alongside GH optimization, or when cost is a driver (oral MK-677 is typically less expensive than compounded injectable sermorelin).

Neither agent replaces recombinant human GH in patients with confirmed AGHD meeting the Endocrine Society's diagnostic criteria [18]. Secretagogues depend on a functioning pituitary. If stimulation testing shows a peak GH below 3 ng/mL, secretagogues are unlikely to produce meaningful IGF-1 normalization regardless of which agent is used [18].